Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.79 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938547 | 1.00 | HTR2C (0.79) | HTR2CHTR3AP2RY14TMEM97HTR2A | |
| SCHEMBL16660400 | 1.00 | HTR2C (0.79) | HTR2CHTR3AP2RY14TMEM97HTR2A | |
| Hydrochloric Acid SCHEMBL4573167 | 0.98 | HTR2C (0.80) | HTR2CHTR3AP2RY14TMEM97HTR2A | |
| SCHEMBL12809959 | 0.91 | HTR2C (0.66) | HTR2CHTR3AHTR2A | |
| Oxalic Acid SCHEMBL3543097 | 0.91 | HTR2C (0.66) | HTR2CHTR3AP2RY14TMEM97 | |
| Hydrochloric Acid SCHEMBL568208 | 0.89 | HTR2C (0.67) | HTR2CHTR3AHTR2A | |
| Trifluoroacetic Acid SCHEMBL22638730 | 0.89 | HTR2C (0.64) | HTR2CHTR3AP2RY14TMEM97 | |
| SCHEMBL373310 | 0.89 | HTR2C (1.00) | HTR2CP2RY14TMEM97HTR2A | |
| Hydrochloric Acid SCHEMBL381390 | 0.87 | HTR2C (1.00) | HTR2CP2RY14TMEM97HTR2A | |
| SCHEMBL22778147 | 0.86 | HTR2C (0.60) | HTR2CP2RY14TMEM97HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119731162-A | PRMT5 inhibitors | 北京望实智慧科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| CN-112513021-B | ROR gamma antagonist and application thereof in medicines | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-115698009-A | CD73 inhibiting 2,4-dioxopyrimidine compounds | 吉利德科学公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021253098-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021253098-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-11046714-B2 | 2,2-difluorodioxolo A2A receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2021-06-29 | — | — | US | disclosed |
| CN-112513021-A | ROR gamma antagonist and application thereof in medicine | 广东东阳光药业有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20070299071-A1 | Substituted phenyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | US | disclosed |
| US-20070299071-A1 | Substituted phenyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | US | disclosed |
| US-20070299071-A1 | Substituted phenyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | US | disclosed |
| WO-2007147770-A2 | SUBSTITUTED PHENYL METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147770-A2 | SUBSTITUTED PHENYL METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| CN-101056845-A | Substituted aniline derivatives | LUNDBECK & CO AS H (DK) | 2007-10-17 | — | — | CN | disclosed |
| CN-1150165-C | 1-arylsulfonyl-2-aryl-pyrrolidine derivatives for the treatment of central nervous system disorders | - | 2004-05-19 | — | — | CN | disclosed |
| CN-1345311-A | 1-arenesulfonyl-2-aryl-pyrolidine and piperidine derivatives for treatment of CNS disorders | HOFFMANN LA ROCHE (CH) | 2002-04-17 | — | — | CN | disclosed |
| US-5861416-A | TREATMENT OF ASTHMA OR COUGH | MERRELL PHARMACEUTICALS INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5824690-A | TREATING ASTHMA, COUGH | HOECHST MARION ROUSSEL INC. (US) | 1998-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227428-A1 | AMIDO COMPOUNDS | RIPK1, RIPK3, MLKL | HTR2C 4642/4885HTR3A 3838/4885P2RY14 1619/4885 |
| US-20070299071-A1 | Substituted phenyl methanone derivatives | CYP11B1, CYP11B2, MC2R | HTR2C 70/4885HTR3A 72/4885P2RY14 1373/4885 |
| US-11046714-B2 | 2,2-difluorodioxolo A2A receptor antagonists | ADORA2A, ADORA2B, ADORA3 | HTR2C 6/4885HTR3A 15/4885P2RY14 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.